Catalogue Number
BN-O1221
Analysis Method
Specification
99%(HPLC)
Storage
-20℃
Molecular Weight
373.36
Appearance
Powder
Botanical Source
Structure Type
Category
SMILES
C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Synonyms
ICL-670/Exjade/Deferasirox
IUPAC Name
Density
1.4±0.1 g/cm3
Solubility
Flash Point
360.3±34.3 °C
Boiling Point
672.1±65.0 °C at 760 mmHg
Melting Point
260-262ºC
InChl
InChl Key
FMSOAWSKCWYLBB-VBGLAJCLSA-N
WGK Germany
RID/ADR
HS Code Reference
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:201530-41-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
29999871
Deferasirox
2019 Feb 7.
29071014
Thallium and its compounds are a class of highly toxic chemicals that cause wide-ranging symptoms such as gastrointestinal disturbances; polyneuritis; encephalopathy; tachycardia; skin eruptions; hepatic, renal, cardiac, and neurological toxicities; and have mutagenic and genotoxic effects. The present research aimed to evaluate the efficacy of the chelating agents deferasirox (DFX) and deferiprone (L1) in reducing serum and tissue thallium levels after the administration of thallium (III), according to two different dosing regimens, to several groups of Wistar rats for 60 days. It was hypothesized that the two chelators might be more efficient as a combined therapy than as monotherapies in removing thallium (III) from the rats’ organs. The chelators were administered orally as either single or combined therapies for a period of 14 days. Serum and tissue thallium (III) and iron concentrations were determined by flame atomic absorption spectroscopy. Serum and tissue thallium (III) levels were significantly reduced by combined therapy with DFX and L1. Additionally, iron concentrations returned to normal levels and symptoms of toxicity decreased.
Thallium (III), Chelation therapy, Deferasirox, Deferiprone, Toxic metal, Serum
Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
Samie Salehi, Amir Sh. Saljooghi, Somayeh Badiee, and Mojtaba Mashmool Moqadam
2017 Oct;
23887830
Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together. Various iron chelating agents are being used for treatment of hemochromatosis which arises from excess iron accumulation. This study was conducted with the aim of determining whether deferasirox used as an iron chelator in patients with hemochromatosis has genotoxic effects. Commercial form of deferasirox, Exjade was used as test material. Test material showed a general mutagen character in mutant strains of Salmonella typhimurium. Deferasirox has also led to an increase in mutagenity-related polymorphic band count in random amplification of polymorphic DNA test done with bone marrow cells of rats. Similarly, test material has increased micronucleus formation in cultured in vitro human peripheral lymphocytes particularly in 48 h period. Consistently with the abovementioned findings, deferasirox reduced nuclear division index (NDI) compared to controls and some part of these reductions are statistically significant. NDI reductions were found at positive control levels at high concentrations.
Iron chelator, Deferasirox, Genotoxicity, Reversion test, RAPD test, Micronucleus test
Signs of deferasirox genotoxicity
Hasan Basri Ila,corresponding author Mehmet Topaktas, Mehmet Arslan, and Mehmet Buyukleyla
2014 Aug;
Description :
Empty ...